AU2008256562A1 - Combination of CHK and PARP inhibitors for the treatment of cancers - Google Patents

Combination of CHK and PARP inhibitors for the treatment of cancers Download PDF

Info

Publication number
AU2008256562A1
AU2008256562A1 AU2008256562A AU2008256562A AU2008256562A1 AU 2008256562 A1 AU2008256562 A1 AU 2008256562A1 AU 2008256562 A AU2008256562 A AU 2008256562A AU 2008256562 A AU2008256562 A AU 2008256562A AU 2008256562 A1 AU2008256562 A1 AU 2008256562A1
Authority
AU
Australia
Prior art keywords
alkyl
cancer
optionally substituted
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008256562A
Other languages
English (en)
Inventor
Mark James O'connor
Graeme Cameron Murray Smith
Sonya Zabludoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2008256562A1 publication Critical patent/AU2008256562A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008256562A 2007-05-25 2008-05-23 Combination of CHK and PARP inhibitors for the treatment of cancers Abandoned AU2008256562A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94020307P 2007-05-25 2007-05-25
US60/940,203 2007-05-25
PCT/GB2008/050372 WO2008146035A1 (en) 2007-05-25 2008-05-23 Combination of chk and parp inhibitors for the treatment of cancers

Publications (1)

Publication Number Publication Date
AU2008256562A1 true AU2008256562A1 (en) 2008-12-04

Family

ID=39672970

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008256562A Abandoned AU2008256562A1 (en) 2007-05-25 2008-05-23 Combination of CHK and PARP inhibitors for the treatment of cancers

Country Status (11)

Country Link
US (1) US20100249112A1 (https=)
EP (1) EP2167086A1 (https=)
JP (1) JP2010527981A (https=)
KR (1) KR20100020981A (https=)
CN (1) CN101743003A (https=)
AU (1) AU2008256562A1 (https=)
BR (1) BRPI0811059A2 (https=)
CA (1) CA2687786A1 (https=)
MX (1) MX2009012705A (https=)
RU (1) RU2009147819A (https=)
WO (1) WO2008146035A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081778A1 (en) * 2009-01-17 2010-07-22 Universität Zürich Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
HUE030613T2 (en) 2012-12-31 2017-05-29 Cadila Healthcare Ltd Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
JP7273791B2 (ja) 2017-04-10 2023-05-15 シエラ オンコロジー， インコーポレイテッド 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
WO2019194738A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
WO2022000946A1 (zh) * 2020-06-29 2022-01-06 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN112375070B (zh) * 2020-06-29 2023-03-28 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
PL2305221T3 (pl) * 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
ATE501138T1 (de) * 2004-01-05 2011-03-15 Astrazeneca Ab Thiophenderivate als chk-1-inhibitoren
US20060204981A1 (en) * 2005-01-07 2006-09-14 Chiang Li Compositions for modulation of PARP and methods for screening for same
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage

Also Published As

Publication number Publication date
WO2008146035A1 (en) 2008-12-04
BRPI0811059A2 (pt) 2017-05-09
CN101743003A (zh) 2010-06-16
CA2687786A1 (en) 2008-12-04
US20100249112A1 (en) 2010-09-30
EP2167086A1 (en) 2010-03-31
KR20100020981A (ko) 2010-02-23
RU2009147819A (ru) 2011-06-27
JP2010527981A (ja) 2010-08-19
MX2009012705A (es) 2009-12-08

Similar Documents

Publication Publication Date Title
AU2008256562A1 (en) Combination of CHK and PARP inhibitors for the treatment of cancers
AU2004220321B2 (en) Phthalazinone derivatives
AU2010364807B2 (en) Heterocyclic derivates, preparation processes and medical uses thereof
AU2011288876B2 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
EP4421076A1 (en) Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
CA2691459A1 (en) Phthalazinone derivatives as inhibitors of parp-1
CN106170289A (zh) 作为蛋白质激酶的调节剂的二芳基巨环
JP2009512671A (ja) ４−ヘテロアリールメチル置換されたフタラジノン誘導体
JP2022550070A (ja) 置換された縮合芳香環誘導体、その組成物、およびそれらの使用
KR20070057859A (ko) 4-헤테로아릴메틸 치환된 프탈라지논 유도체
WO2008114023A2 (en) Phthalazinone derivatives
JP2010523633A (ja) フタラジノン誘導体および癌を治療するための医薬としてのその使用
KR20210153051A (ko) 매크로사이클릭 화합물
JP7323218B2 (ja) 置換された縮合芳香環誘導体、その組成物、およびそれらの使用
AU2008299721A1 (en) Phthalazinone derivatives
CN109715166A (zh) 癌症的治疗
CN110272419A (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
EP3653622A1 (en) Aminopyrimidine compound and composition comprising same and use thereof
CN115836077B (zh) 氧杂氮杂螺环类衍生物、其制备方法及其在医药上的应用
EP3878841B1 (en) Indazole kinase inhibitor and use thereof
US12404244B2 (en) Pan-KIT kinase inhibitor having quinoline structure and application thereof
CN113754685B (zh) 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用
CA3259052A1 (en) HETEROCYCLIC COMPOUNDS USED AS PI3K.ALPHA INHIBITORS.
HK40009984A (en) Erbb inhibitors and uses thereof
WO2008146036A1 (en) Combination of checkponit kinase ( chk) and telangiectasia mutated (atm) inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted